• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-SNCA antibody :: Mouse alpha Synuclein Monoclonal Antibody

Scan QR to view Datasheet
Catalog # MBS500025
Unit / Price
  0.1 mL  /  $360 +1 FREE 8GB USB
Testing Data
Product Name

alpha Synuclein (SNCA), Monoclonal Antibody

Also Known As

Anti-alpha Synuclein

Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Immunogen Sequence Length
140
Chromosome Location
Chromosome: 4; NC_000004.12 (89724099..89838296, complement). Location: 4q21
OMIM
127750
3D Structure
ModBase 3D Structure for P37840
Clonality
Monoclonal
Isotype
IgG1
Clone Number
3H9
Host
Mouse
Species Reactivity
Human, mouse, rat
Specificity
Specific for the ~15kDa alpha Synuclein protein.
Purity/Purification
Ascites fluid (Mouse ascites fluid.)
Form/Format
100 ul liquid. Contains 10 mM sodium azide.
Antigen
Full length human alpha synuclein expressed in E. Coli.
Immunogen Information
Full length human alpha synuclein expressed in E. Coli.
Immunogen Species
Human
Reactivity Assumed Based on 100% Sequence Homology
Most mammals
Species Reactivity Note
The antibody has been directly tested for reactivity in human and rodent. It is expected that it will work on other mammal tissues.
Biological Significance
Alpha-synuclein is a presynaptic neuronal protein that is thought to be involved in the formation of SNARE complexes. Most significantly, aggregated alpha-synuclein is one of the major components found in the Lewy bodies that occur in Parkinson's disease (PD) and other neurodegenerative disorders (Okochi et al., 2000). Early onset Parkinson's disease may be caused by a duplication or triplication of one of the alpha synuclein genes (Chartier-Harlin MC et al., 2004 and Singleton, AB et al., 2005). Alpha-synuclein is also found in the Lewy bodies of patients with diffuse Lewy body disease and inclusions in glial cells in the brains of patients with multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS).
Preparation and Storage
Store at -20 degree C in undiluted aliquots; stable for at least one year. Avoid freeze/thaw cycles.
Other Notes
Small volumes of anti-SNCA antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-SNCA antibody
Mouse monoclonal antibody
Applications Tested/Suitable for anti-SNCA antibody
Western Blot (WB), Immunofluorescence (IF)
Application Notes for anti-SNCA antibody
Quality Control: Western blots performed on each lot.
WB: 1:1,000
IF: 1:500

Testing Data of anti-SNCA antibody
anti-SNCA antibody Testing Data image
NCBI/Uniprot data below describe general gene information for SNCA. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
15
NCBI Official Full Name
alpha-synuclein isoform NACP140
NCBI Official Synonym Full Names
synuclein, alpha (non A4 component of amyloid precursor)
NCBI Official Symbol
NCBI Official Synonym Symbols
PD1; NACP; PARK1; PARK4
  [Similar Products]
NCBI Protein Information
alpha-synuclein; synuclein alpha-140; non A-beta component of AD amyloid
UniProt Protein Name
Alpha-synuclein
UniProt Synonym Protein Names
Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor
Protein Family
UniProt Gene Name
UniProt Synonym Gene Names
NACP; PARK1; NACP  [Similar Products]
UniProt Entry Name
SYUA_HUMAN
NCBI Summary for SNCA
Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]
UniProt Comments for SNCA
Function: May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.

Subunit structure: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1

By similarity. Interacts with phospholipase D and histones. Ref.16 Ref.18

Subcellular location: Cytoplasm. Membrane. Nucleus. Cell junction › synapse. Note: Membrane-bound in dopaminergic neurons. Ref.18 Ref.22

Tissue specificity: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.

Domain: The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments. Ref.23

Post-translational modification: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. Ref.13 Ref.14 Ref.15 Ref.17 Ref.21Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.Ubiquitinated. The predominant conjugate is the diubiquitinated form

By similarity.Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure. Ref.26

Involvement in disease: Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.Parkinson disease 1 (PARK1) [MIM:168601]: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.28 Ref.29 Ref.30 Ref.32 Ref.33Parkinson disease 4 (PARK4) [MIM:605543]: A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.Note: The disease is caused by mutations affecting the gene represented in this entry.Dementia Lewy body (DLB) [MIM:127750]: A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.Note: The disease is caused by mutations affecting the gene represented in this entry.

Sequence similarities: Belongs to the synuclein family.
Product References and Citations for anti-SNCA antibody
• Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem Jan 7;275(1): 390-7.
• Chartier-Harlin, MC. et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169 (2004).
• Singleton, AB et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302: 841 (2003).

Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000